• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

IntelGenx to reclaim global rights to oral thin-film migraine treatment

December 19, 2017 By Sarah Faulkner

IntelGenxIntelGenx (CVE:IGX) is slated to regain exclusive global rights to develop and sell its Rizaport oral thin-film acute migraine treatment in January, according to a report from BioTuesdays.

The company’s partner, RedHill Biopharma (NSDQ:RDHL), has decided to end its co-development and commercialization relationship with IntelGenx, the news site reported.

“We were expecting RedHill’s decision because in recent years RedHill has been increasingly focused on its gastrointestinal projects and it has started reallocating its resources accordingly,” IntelGenx president & CEO Horst Zerbe told BioTuesdays.”Because of that revised product strategy, this decision did not come out of the blue. RedHill has considered Rizaport to be a non-core asset for some time.”

IntelGenx’s Rizaport therapy uses the company’s VersaFilm oral film technology and was designed to be a therapeutic option for patients with migraine-related nausea and for migraine patients who may have difficulty swallowing pills.

“Rizaport is a fully developed product with no remaining development work outstanding. Going forward there is only upside for us as we don’t need to share any future payments from licensing fees and royalties,” IntelGenx’s VP of business & corporate development, Dana Matzen, told BioTuesdays.

RedHill plans to quickly transfer the rights and obligations for Rizaport back to IntelGenx, Zerbe said, including the product’s pending NDA submission. Meanwhile, IntelGenx will continue to look for prospective commercial partners for Rizaport in the U.S., Europe and other territories, the chief executive added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: IntelGenx, redhillbiopharma

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS